



Form PTO-1449

Pocket Number: D-2971

APPLN NO.: 08/954,810

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
(Use several sheets if necessary)

Applicant: Voat

Filing Date: 9/17/01

Group Art Unit: 1814

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	RULING DATE IF APPROPRIATE
CMK	5	4	3	7	2	9	1	08/01/95	Pasricha et al.	128	898	
	5	7	0	7	6	4	2	01/13/98	Yue	424	423	
	5	7	1	4	4	6	8	02/03/98	Blinder	514	898	
	5	7	6	6	6	0	5	06/16/98	Sanders et al.	424	239	
	5	8	6	3	5	5	2	01/26/99	Yue	424	423	
	5	9	6	2	4	7	9	10/05/99	Chen	514	348	
	5	9	8	9	5	4	5	11/23/99	Foster et al.	424	183	
	6	0	0	9	8	7	5	01/04/00	Hubbard, Jr.	128	898	
	6	0	6	3	7	6	8	05/16/00	First	514	14	
	6	1	1	3	9	1	5	09/05/01	Aoki et al.	424	236	
	6	1	3	6	5	5	1	10/24/00	Aoki	435	732	
	6	1	7	4	8	8	0	01/16/01	Bernstein	514	217	
CMK	6	2	0	1	0	2	2	03/13/01	Mease et al.	514	560	

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO	94/	1	5	6	2	9					YES	NO
CMK	WO	94/	1	5	6	2	9	07/21/94	International				
	WO	95/	1	7	9	0	4	07/06/95	International				
CMK	WO	99/	0	3	4	8	3	01/28/99	International				

**OTHER DOCUMENTS**

CMK		Raj: <i>Pain Digest</i> , 1998; 6: 357-363, Diagnosis and Management of Fibromyalgia and Myofascial Pain Syndrome.
		Wiegand et al: <i>Naunyn-Schmiedeberg's Arch. Pharmacol</i> , 1976; 292: 161-165, I-Labeled Botulinum A Neurotoxin: Pharmacokinetics in Cats after Intramuscular Injection.
		Haberman: <i>Naunyn-Schmiedeberg's Arch. Pharmacol</i> , 1974; 281: 47-56, I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord.
		Mantyh: <i>Annals New York Academy of Science</i> ; Part V: 263-270, Substance P and the Inflammatory and Immune Response.
		Spiegelman & Pull: <i>Annals New York Academy of Science</i> ; 220-228, Substance P Actions on Sensory Neurons.
CMK		M.K. Childers et al: <i>Journal of Back and Musculoskeletal Rehabilitation</i> , 1998; 10: 89-96, Treatment of painful muscle syndromes with Botulinum toxin: A review.

EXAMINER

*Chen/r*

DATE CONSIDERED

*10/11/02*

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

*Chen/r**1/18/05**10/666,408***RECEIVED**  
MAR 04 2002  
TECH CENTER 1600/2900

FEB 28 2002

Sheet 2 of 2

Form PTO-1449

POCKET NO: D-2971

APPLN. NO.: 09/954,610

# INFORMATION DISCLOSURE CITATIONS IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT: Voel

FILING DATE: 09/17/01

GROUP ART: 1614 1656

## U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	RECEIVED	FILING DATE
						MAR 04 2002	
						TECH CENTER 1600/2900	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

## OTHER DOCUMENTS

CHK		Paulson et al: <i>Movement Disorders</i> , 1996; 11(4): 459, Botulinum Toxin Is Unsatisfactory Therapy for Fibromyalgia.
		Giladi: <i>Journal of Neurological Sciences</i> , 1997; 152: 132-135, The Mechanism of action of Botulinum toxin type A in Focal dystonia is most probably through its dual effect in efferent ( motor ) and afferent pathways at the injected site.
		Welch et al: <i>Toxicon</i> , 2000; 38: 245-258, Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins.
		R. Staud et al: <i>Pain</i> , 2001; 91: 165-175, Abnormal sensitization summation of second pain ( wind-up ) in patients with fibromyalgia syndrome.
		Jerome Groopman: <i>The New Yorker</i> , November 13, 2001; 78-92, Hurting all over
		Freund et al: <i>J Oral Maxillofac Surg</i> , 1999; 57: 916-920, The Use of Botulinum Toxin for the Treatment of Temporomandibular Disorders: Preliminary Findings.
		Keller et al: <i>The Journal of Biological Chemistry</i> , 2001; 276( No. 16): 13476-13482, The Role of the Synaptic Protein SNAP-25 in the Potency of Botulinum Neurotoxin Type A.
		Binder et al: <i>Movement Disorders</i> , 13 (Suppl 2): 241:1998, Botulinum Toxin Type A (BTX).
		Siberstein et al: <i>Headache</i> , 40;445-450:2000, Botulinum Toxin Type A as a Migraine Preventive Treatment.
		Relja: <i>Eur. Journal of Neurology</i> , 4 (Suppl 2) S71-73: 1997, Treatment of Tension-Type Headache by Local Injection of Botulinum Toxin.
		Cheshire et al: <i>Pain</i> , 59:65-69:1994, Botulinum Toxin in the Treatment of Myofascial Pain Syndrome.
		Fillippi et al: <i>Acta Otolaryngologica</i> 113;400-404: 1993, Effects on Rat Jaw Muscle Spindles.
CMC		Nix et al: <i>Neurology</i> 42;602-606 (1992)

EXAMINER

Chen

DATE CONSIDERED:


10/1/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Chen

8/18/05

10/666,408



RECEIVED Sheet 1 of 1

DEC 17 2001

SUPPLEMENTAL  
LIST OF ART CITED BY APPLICANT

TECH CENTER 1600/2900

ATTY. DOCKET: 17455 (BOT)	SERIAL NO.: 09/954,610 10/666408
APPLICANT: VOET	TITLE: METHODS FOR TREATING FIBROMYALGIA
FILING DATE: SEPTEMBER 17, 2001	GROUP: 1614 1656

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						
	BB						

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

CYK

CYK	CA	ASHERSON, R.A., et al., <i>The Use of Botulinum Toxin-A in the Treatment of Patients with Fibromyalgia</i> , The Journal of Rheumatology 2001; July; 28 : 7 page 1740.
	CB	
	CC	

EXAMINER

*CBH*

DATE CONSIDERED

*3/7/02*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*CBH*

*8/18/05*